Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000412742 | SCV000491683 | pathogenic | not provided | 2024-02-26 | criteria provided, single submitter | clinical testing | Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: Lee2020[Abstract], 27494029, 35918040, 34327338, 25782670) |
Center for Pediatric Genomic Medicine, |
RCV000412742 | SCV000510862 | pathogenic | not provided | 2016-07-15 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001797714 | SCV002040996 | pathogenic | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001797714 | SCV004296674 | pathogenic | Tuberous sclerosis 2 | 2024-10-30 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 34 of the TSC2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TSC2 are known to be pathogenic (PMID: 10205261, 17304050). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with tuberous sclerosis complex (PMID: 25782670). ClinVar contains an entry for this variant (Variation ID: 373118). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |